GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners
17.12.2025 03:00:00 CET | Business Wire | Press Release
GE HealthCare (Nasdaq: GEHC) today announced it will supply more than 300 CT (computed tomography) scanners under Indonesia’s Strengthening Indonesia’s Health Referral Network (SIHREN) program to deliver equitable, high-quality care to more than 280 million Indonesians. As part of a competitively awarded, multi-year contract, GE HealthCare will supply the advanced CT scanners to public hospitals across all 38 provinces, including urban and remote areas. The CT scanner procurement under SIHREN was conducted through a fully competitive international tender process governed by the World Bank’s procurement regulations.
SIHREN is the largest healthcare infrastructure investment in Indonesia’s history and among the largest multilateral health projects globally. SIHREN aims to modernize the national referral system and expand access to diagnostics and treatment across the archipelago, with a focus on non-communicable diseases (NCD) management, maternal health, and pandemic resilience.
By modernizing the referral network and expanding access to advanced diagnostics across all provinces, the collaboration is bringing equitable, high-quality care closer to every community—urban and remote alike. Access to life-saving CT technology will enable early detection and timely treatment of critical conditions such as cancer, stroke, and heart disease, helping save lives and improve health outcomes for Indonesians nationwide.
“We are proud to support the Indonesian Ministry of Health’s vision,” said Elie Chaillot, President & CEO, International at GE HealthCare. “Our ongoing investments in local manufacturing, capacity building and training reflect our commitment to contribute to Indonesia’s healthcare resilience and drive local economic growth. Equally important, this initiative helps ensure that advanced diagnostic technologies reach rural and remote communities, promoting healthcare equity and bringing life-saving care closer to every Indonesian.”
CT scanners have become essential in modern healthcare. Using X-ray beams and advanced computer processing, CT scanners provide fast, detailed 2D and 3D images of the internal organs, bones, blood vessels, and soft tissues, helping doctors diagnose injuries and illnesses quickly. CT technology enables early detection of conditions, determines the size and spread of tumors or infections, monitors treatment effectiveness (such as chemotherapy or radiotherapy), and guides procedures like biopsies in deep organs.
To deepen its local footprint, GE HealthCare recently inaugurated a production facility in Bogor, in collaboration with PT Kalbe Farma’s subsidiary, Forsta. This local manufacturing facility is aimed at strengthening Indonesia’s supply chain resilience, supporting technology transfer and helping develop a skilled local healthcare and technical workforce.
For over seven decades, GE HealthCare has collaborated with Indonesia’s public and private healthcare sectors. In early 2025, GE HealthCare was awarded a tender to supply 10 1.5T MR systems to public hospitals. High resolution MR imaging enables early, accurate diagnosis and ongoing monitoring of conditions like cancer, stroke and heart disease, and is critical for effective non-communicable disease management.
In 2024, GE HealthCare established the Regional Innovation & Training Experience (RITE) Hub in Jakarta. The center provides Indonesian healthcare professionals with hands-on training on advanced imaging technologies, including MR and CT systems, and collaborates with leading educational institutions to deliver programs covering device operation and clinical pathways. By equipping clinicians with practical skills and knowledge, the center strengthens local expertise and ensures medical technologies are used to their maximum potential across Indonesia.
About GE HealthCare Technologies Inc.
GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251216956209/en/
Contacts
GE HealthCare Media Contact:
Junaidah Dahlan
M +65 93367798
Junaidah.dahlan@gehealthcare.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma’s Morcamilast (ME3183) was Granted Orphan Medicinal Product Designation by the European Commission for Palmoplantar Pustulosis3.3.2026 02:00:00 CET | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that morcamilast (proposed international nonproprietary name; development code: ME3183), a selective phosphodiesterase-4 (PDE4) inhibitor, has been granted orphan medicinal product designation by the European Commission (EC) for the treatment of palmoplantar pustulosis (PPP). Palmoplantar pustulosis is a chronic inflammatory disease characterized by the development of multiple sterile pustules on the palms and soles. Patients often experience pain and pruritus of the skin, and the condition can be accompanied by nail involvement and joint pain. Because lesions on the palms are visible to others and lesions on the soles can cause pain while walking, daily functioning can be significantly restricted, leading in a substantial reduction in quality of life. PPP has a pathophysiology distinct from psoriasis and pustular psoriasis, and treatment can be challenging, unde
Yubico Establishes Singapore as Third Global Headquarters Accelerating Asia Pacific Growth3.3.2026 01:00:00 CET | Press Release
Yubico (NASDAQ STOCKHOLM: YUBICO), a cybersecurity company, inventor of FIDO passkeys and creator of the YubiKey, the most secure passkey, today announced the opening of its third global headquarters in Singapore. This announcement reinforces Yubico’s long-term commitment to the Asia Pacific region and builds on its role in advancing open authentication standards, while shaping a safer digital world for all. The new office complements Yubico’s existing global headquarters in Stockholm, Sweden and Santa Clara, USA, reflecting its strategy to serve a growing international user base by helping customers deploy YubiKeys at scale to adapt to a rapidly evolving cybersecurity landscape. “As the digital economy grows, there’s a decisive shift across Asia Pacific, where organizations are moving beyond legacy multi-factor authentication to meet rigorous new national regulations for identity protection,” said Jerrod Chong, Acting Chief Executive Officer at Yubico, a Singaporean. “The expansion of
IFF Completed the Divestiture of Soy Crush, Concentrates and Lecithin Businesses2.3.2026 22:15:00 CET | Press Release
IFF (NYSE: IFF) today announced that it has successfully completed the previously announced divestiture of its soy crush, concentrates and lecithin businesses to Bunge. This transaction does not include IFF’s soy isolates business. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260302231096/en/
Verimatrix ReAccess Earns Gold 2026 Merit Award for Telecom & Wireless2.3.2026 17:50:00 CET | Press Release
Regulatory News: Verimatrix (Euronext Paris: VMX), a leading provider of security solutions for a safer connected world, today announced that its Verimatrix ReAccess solution was honored with a gold 2026 Merit Award for Telecom & Wireless. The industry accolade recognizes the company’s next-generation content security solution that modernizes legacy Conditional Access Systems (CAS) across DVB, IPTV and OTT networks without requiring costly hardware replacements or field service interventions. Judged by industry executives, media professionals and technology consultants, the Merit Awards evaluate submissions from across the telecommunications landscape. Verimatrix ReAccess enables secure, over-the-air (OTA) software updates to deployed set-top boxes (STBs), delivering operator cost savings, reduced operational complexity, and ongoing protection against piracy. It also empowers operators to continuously strengthen content security, eliminating the need for costly hardware replacements. U
Textron Aviation Launches Donation Campaign to Support 2026 Special Olympics Airlift; Continues Nationwide Call for Volunteer Doves2.3.2026 17:00:00 CET | Press Release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced the launch of a donation campaign benefitting Special Olympics in support of the 2026 Special Olympics Airlift, a nationwide effort that brings athletes and coaches to the Special Olympics USA Games through the generosity of volunteer pilots, aircraft owners and operators known as Doves. Financial contributions go directly to the Special Olympics, a 501(c)(3) charitable organization. New for the 2026 event, the donation campaign serves a vital role in ensuring each delegation has what it needs for a smooth and welcoming travel experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302196418/en/ Textron Aviation launches donation campaign to support 2026 Special Olympics Airlift; continues nationwide call for volunteer Doves (Photo credit: Textron Aviation). “This campaign reflects the spirit of unity and generosity that defines the Special Olym
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom